TED Ted Baker Plc

    RNS Number : 2639K
  Tepnel Life Sciences PLC
  17 December 2008
   


    Tepnel Life Sciences plc ("Tepnel" or the "Company")

    Additional Listing and TVR


    
Manchester, UK * 17 December 2008: Tepnel Life Sciences PLC (AIM: TED), the UK-based international Molecular Diagnostics and Research
Products & Services group, was informed that 4,420,000 warrants have been converted by warrantholders into new ordinary shares of 1p each
(*New Ordinary Shares*) at an exercise price of 6.98p per share and 1,140,226 warrants have been converted by warrantholders into new
ordinary shares of 1p each (*New Ordinary Shares*) at an exercise price of 8.05p per share.

    The New Ordinary Shares have been issued and allotted as fully paid up and rank pari passu in all respects with the existing issued
ordinary share capital of the Company.

    Application has been made by the Company for the admission of the 5,560,226 New Ordinary Shares to be admitted to the AIM market.  It is
expected that Admission will become effective and that dealings in the New Ordinary Shares on AIM will commence on 23 December 2008.

    Following Admission of the New Ordinary Shares, the total number of ordinary shares in issue and therefore the total number of voting
rights will be 238,940,801.



    For Further Information:

    Tepnel Life Sciences plc
    Ben Matzilevich, CEO
    Michael Slater, Group Finance Director
    Carol Smith, Group Marketing Communications Manager
    0161 946 2200

    Capital MS&L
    Mary Clark or Joey Whineray
    Tel: +44 20 7307 5330

    Seymour Pierce Limited
    Mark Percy
Tel: +44 20 7107 8000





    Notes to Editors

    About Tepnel Life Sciences plc
    Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services group with two main divisions, Molecular
Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France over 200
employees.  Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and
Biomedical Research.  The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. 
Tepnel focuses on these niche opportunities with internally developed products, patents, expertise and know-how as well as strategic
acquisitions, to develop a leadership position within these defined market segments.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
IOEDQLFFVLBXFBV

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024